Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02014103
Recruitment Status : Completed
First Posted : December 18, 2013
Last Update Posted : March 14, 2016
Sponsor:
Collaborators:
University of Colorado, Denver
Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
Rita Alloway, University of Cincinnati

Brief Summary:

Conduct a retrospective study to evaluate the impact of generic conversion in adult transplant recipients on post transplant outcomes one year prior to conversion to one year post conversion. Variables for analysis will include but not limited to incidence of rejection, hospital admission, changes in renal function, changes in transplanted organ function. All tacrolimus levels and dose changes during this period will be collected and compared. Additional pharmacokinetic modeling of this data will be performed for comparison.

The prospective study will compare othe relative bioavailability and steady-state pharmacokinetics of 6 tacrolimus formulations in a prospective, 6-way cross-over study including CYP3A5 expressors (n=30) and non-expressor (n=30) transplant patients.


Condition or disease Intervention/treatment Phase
Complication of Transplant Drug: Tacrolimus Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Clinical and Safety Outcomes Associated With Conversion From Brand-Name to Generic Tacrolimus Products in High Risk Transplant Recipients
Study Start Date : March 2015
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Tacrolimus

Arm Intervention/treatment
Sequence 1
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation 3, 5, 6, 4, 2, 1.
Drug: Tacrolimus
Administration of each formulation will be determined by sequence.
Other Name: Prograf

Sequence 2
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation 3, 4, 6, 5, 1, 2.
Drug: Tacrolimus
Administration of each formulation will be determined by sequence.
Other Name: Prograf

Sequence 3
Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation 4, 3, 5, 1, 6, 2.
Drug: Tacrolimus
Administration of each formulation will be determined by sequence.
Other Name: Prograf




Primary Outcome Measures :
  1. Compare pharmacokinetic parameters of each tacrolimus formulation in transplant recipients [ Time Frame: December 2014 (up to one year) ]
    To estimate the ratio of C0, C12, AUC0-12h and Cmax and apply CI testing at steady state between all tacrolimus formulation combinations in transplant subjects.


Secondary Outcome Measures :
  1. To compare the safety and efficacy of each tacrolimus formulation in stable transplant subjects [ Time Frame: December 2014 (up to one year) ]
    Conduct safety lab testing specific to transplanted organ function and clinical assessments for adverse events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. 18 years or older
  2. Able to participate and willing to give written informed consent/ assent/ consent by parent or legal guardian and to comply with the study visits and restrictions.
  3. Subject who has received a primary or secondary transplant.
  4. Subject who is at least 6 months post-transplant and on a stable dose of tacrolimus as defined by physician, one tacrolimus trough level within the physician defined target range within past 6 months and one additional trough level during the screening period within 30% of the physician defined target range.
  5. BMI less than or equal to 40.

Exclusion criteria

  1. Evidence of any acute rejection
  2. Subjects who require dialysis within 6 months prior to study entry
  3. Recipients of multiple organ transplants
  4. Subjects who have tested positive for HBsAG or HIV, or who are recipients of organ from donors who are known to be HBsAG or HIV positive. Virology screening at the time of transplant.
  5. HepC positive subjects with liver biopsy proven recurrent disease considered relevant by physician oversight.
  6. Subjects with any severe medical condition requiring acute or chronic treatment that in the investigator's opinion would interfere with study participation
  7. History of malignancy, treated or untreated, with the past 2 years with the exception of carcinoma in situ or excised basal cell carcinoma, or hepatocellular carcinoma prior to transplant.
  8. GFR ≤ 35 ml/min measured as estimated using the MDRD4 formula
  9. Subjects with AST, ALT, total bilirubin ≥ 3 X ULN or other evidence of severe liver disease
  10. Subjects with white blood cell (WBC) count ≤2,000/ mm3 or with thrombocytopenia (platelet count ≤ 75,000/ mm3), with an absolute neutrophil count of ≤ 1,500/ mm3 or hemoglobin <8g/dL)
  11. Subjects with clinically significant infections, requiring therapy, which, in the investigator's opinion, would interfere with the objectives of the study
  12. Other mental or physical conditions which in the investigator's opinion, are considered clinically significant
  13. Presence of intractable immunosuppressant complications or side effects resulting in dose adjustment of tacrolimus
  14. Subjects who have been exposed to an investigational therapy within 30 days prior to enrollment or 5 half-lives of the investigational product, whichever is greater.
  15. An anticipated change in the immunosuppressive regimen during subject participation other than that required by the protocol
  16. Subject with severe GI disturbance or diarrhea which could interfere with tacrolimus absorption
  17. Severe diabetic gastroparesis
  18. Initiation of any medications that could interfere with tacrolimus blood levels, including OTC medications, herbal supplements, grapefruit or grapefruit juice.
  19. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive BhCG laboratory test (> 5 mIU/mL)
  20. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are: 1) women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; 2)women whose partners have been sterilized by vasectomy or 3)using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs); periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02014103


Locations
Layout table for location information
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
University of Cincinnati
University of Colorado, Denver
Children's Hospital Medical Center, Cincinnati
Investigators
Layout table for investigator information
Principal Investigator: Rita R Alloway, PharmD University of Cincinnati

Layout table for additonal information
Responsible Party: Rita Alloway, Research Professor, University of Cincinnati
ClinicalTrials.gov Identifier: NCT02014103     History of Changes
Other Study ID Numbers: 13-223-SOL-00102
FDA ( Other Grant/Funding Number: HHSF223201310224C )
First Posted: December 18, 2013    Key Record Dates
Last Update Posted: March 14, 2016
Last Verified: March 2016
Keywords provided by Rita Alloway, University of Cincinnati:
bioequivalence
tacrolimus
transplant
CYP3A5 expressors/non expressors
Additional relevant MeSH terms:
Layout table for MeSH terms
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action